Your AI-Trained Oncology Knowledge Connection!
Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com
The emergence of checkpoint inhibitors has transformed the second-line treatment of patients with metastatic bladder cancer. However, questions regarding the utility of immunotherapy in the frontline setting remain unanswered, leaving chemotherapy as the standard-of-care option.
December 14, 2020 - Microsatellite instability–high tumors in patients with endometrial, colorectal, and stomach carcinomas were found to be enriched in recurrent shared, immunogenic, tumor-specific frameshifts expressed on RNA and protein levels.
December 10, 2020 - At 8 years of follow up, fewer deaths and improved cumulative incidence of central nervous system recurrences were reported with adjuvant neratinib compared with placebo in patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy, according to updated results of the phase 3 ExteNET trial.
December 7, 2020 - The addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to improved hematologic complete response rate compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.
December 6, 2020 - Orca-T, a precision Treg-engineered donor product, demonstrated preventive potential for graft-versus-host disease, with less immunosuppression, compared with the standard of care in patients with high-risk hematologic malignancies who underwent hematopoietic stem cell transplantation.
December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.
December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.
December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.
December 2, 2020 - The novel immunotherapeutic vaccine DSP-7888, in combination with pembrolizumab, has been dosed in the first patient with platinum-resistant ovarian cancer.
Laparoscopic distal gastrectomy with D2 lymphadenectomy demonstrated comparable rates of 3-year relapse-free survival vs open distal gastrectomy in patients with locally advanced gastric cancer.
November 25, 2020 - The oral MDM2 antagonist idasanutlin was found to promote expansion of TP53-mutant subclones among patients with polycythemia vera.
Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.
Nusayba Bagegni, MD, discusses prominent data that have emerged in early-stage and metastatic HER2-positive breast cancer.
November 23, 2020 - Patients with microsatellite instable metastatic castration-resistant prostate cancer have a distinct T-cell signature that is detectable in the peripheral blood.
November 23, 2020 — Katherine K. Clifton, MD, discusses the utility of CDK4/6 inhibitors as frontline treatment for patients with HR-positive/HER2-negative breast cancer, the growing role of PI3K inhibitors in this space, and potential future research directions with these treatments.
November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.
November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager, was shown to have a feasible adverse effect profile in patients with small cell lung cancer.
Keith T. Flaherty, MD, discusses the rationale to conduct the NCI-MATCH trial, key findings from the recent publication, and potential permutations of the trial design that could further the role of precision medicine in oncology.
D. Ross Camidge, MD, PhD discusses the role of targeted therapy and how it is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer.
Haiying Cheng, MD, PhD highlights new data from key clinical trials in extensive-stage small cell lung cancer.
African American men with low-risk prostate cancer who received active surveillance had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment compared with non-Hispanic white men.
Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.
Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.
Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.
During the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Sudipto Mukherjee, MD, PhD, MPH, provides detail as to some of these nuances and the optimal management of patients with CML.
A significant decline in cancer screenings, biopsies, surgeries, office visits, and therapies was observed with variation by cancer type and site of service among senior patients with cancer from March to July 2020, during the coronavirus disease 2019 pandemic.
Immunoscore®, a host immune response classification tool, has demonstrated the ability to significantly affect treatment decision-making for patients with stage II colon cancer, particularly among those with high-risk disease.
A novel surgical technique called the “hood technique” for robotic-assisted radical prostatectomy was shown to achieve early return of urinary continence without a negative impact on complications and cancer outcomes among men with localized prostate cancer.
Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a 4-factor prognostic model and considered for a clinical trial.
Manish A. Shah, MD, FASCO, discusses key clinical trials that have evaluated the utility of pembrolizumab and nivolumab in the gastric/gastroesophageal junction cancer, and esophageal squamous cell carcinoma paradigms.
